All In Biotech

Drug Trial Radar · NCT07254481

VB19055 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population

A Phase 1, Randomized, Double-Blind Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, Food Effects, and QT/QTc Interval Impact of VB19055 Tablets in Healthy Chinese Adult Subjects

Last checked: Nov 19, 2026Latest source record: Nov 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

86

Planned (sponsor's estimate)

Start

Oct 5, 2025

Primary completion

Jul 2026

Study completion Jul 2026

Sponsor

Sponsor type
Industry
First posted
Nov 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety,tolerability,pharmacokinetics and pharmacodynamics of VB19055 in the healthy Chinese population.

Conditions

  • Hypertension

Interventions

  • VB19055Drug

    In this part, VB19055 tablets will be administered as a single or multiple oral dose.

  • VB19055 placeboDrug

    In this part, VB19055 placebo tablets will be administered as a single or multiple oral dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of treatment emergent Adverse Events as assessed by CTCAE v5.0Time frame: Average half a month

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Hangzhou First People's Hospital

    Hangzhou, China · Recruiting

  • Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine

    Shanghai, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.